

Expertgruppens förteckning över substanser som utgör dopningsmedel enligt lag (1991:1969) om förbud mot vissa dopningsmedel.

Ursprungslistan upprättad 2006 av Dopinglaboratoriet, Nationellt forensiskt centrum (fd.SKL) och Tullverkets laboratorium. Nyutgåvor fastställs av Expertgruppen för dopningspreparat, administrerad av Folkhälsomyndigheten

Utgåva 16: 2021-03-29 Folkhälsomyndigheten

Substanser som inte finns upptagna i denna förteckning kan ändå utgöra dopningsmedel enligt ovanstående lag.

Expertgruppens förteckning över dopningsmedel

Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
1-testosterone	17-hydroxy-10,13-dimethyl-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one	65-06-5	1	Androgen/anabol steroid	[78,79]
17-methyl-1-testosterone	17β-hydroxy-17α-methyl-5α-androst-1-en-3-one (5α,17β)-17-hydroxy-17-methyl-5α-androst-1-en-3-one	65-04-3	1	Androgen/anabol steroid	[56,57]
Anastrozole	α,α,α',α'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile	120511-73-1	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Androisoxazole	(5α,17β)-17-Methylandrostando[3,2-c]-isoxazol-17-ol 17β-Hydroxy-17α-methylandrostando-[3,2-c]isooxazole Referensrad 2	360-66-7	1	Androgen/anabol steroid	[1] 2[2]
Androstadienedione	1,4-androstadiene-3,17-dione	897-06-3	1	Prohormon Androgen/anabol steroid	[6, 48]
Androstatrienedione	Androsta-1,4,6-trien-3,17-dione	633-35-2	4	Ökar produktion av könshormon, t.ex. testosteron	[3]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Androstenediol	5-Androstene-3 β ,17 β -diol 3 β 17 β -Dihydroxyandrost-5-ene Referensrad 2 Androst-5-ene-3,17-diol Referensrad 3 5 α -androst-1-ene-3 β ,17 β -diol Referensrad 4	521-17-5	1	Androgen/anabol steroid	[1] 2 [4] 3 [5] 4 [6]
Androsterone	3 α -Hydroxy-17-androstanone Androstan-3 α -ol-17-one 1 Androstan-17-one, 3-hydroxy-, (3 α , 5 α)- 2	53-41-8	1	Androgen/anabol steroid	[1] 1 [7] 2 [8]
Arzoxifene	CB-31515928	182133-27-3. (182133-25-1 free base)	4	Ökar produktion av testosteron, (SERM)	[1, 9]
Atamestan	1-Methylandrosta-1,4-diene-3,17-dione;SH-489	96301-34-7	4	Ökar produktion av testosteron. Aromatas inhibitor	[10]
Bazedoxifene	Bazedoxefine 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-. (4-hydroxyphenyl)-3-methyl-1H-indol-5-ol	198481-32-2	4	Ökar produktion av könshormon, t.ex. testosteron, (SERM)	[9, 11]
Bolandiol	3 β ,17 β -Dihydroxyestr-4-ene Dihydroxyestrene Estr-4-ene-3 β ,17 β -diol Referensrad 2 19-norandrostenediol Referensrad 3	19793-20-5	1	Androgen/anabol steroid	[1] 2 [12] 3 [6]
Bolasterone	7 α ,17 α -Dimethyltestosterone 17 β -Hydroxy-7 α ,17-dimethylandrost-4-en-3-one Referensrad 2	1605-89-6	1	Androgen/anabol steroid	[1] 2 [13]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Boldenone	1,4-Androstadien-17 β -ol-3-one 17 β -Hydroxyandrosta-1,4-dien-3-one Referensrad 2 3 Dehydrotestosterone	846-48-0	1	Androgen/anabol steroid	[1] 2 [14] 3 [15]
Calusterone	7 β ,17 α -Dimethyltestosterone 17 β -Hydroxy-7 β , 17 α -dimethylandrosta-4-ene-3-one Referensrad 2 17 α -ethynyl-17 β -hydroxyandrosta-4-eno[2,3-d]isoxazole Referensrad 3	17021-26-0	1	Androgen/anabol steroid	[1, 16] 2 [17] 3 [6]
Chloramiphene	Clomiphene 2-[4-(2-Chloro-1,2-diphenylethenyl)-phenoxy]-N,N-diethylethanamine 2-Chloro-1-(p- β -diethylaminoethoxy)phenyl)-1,2-diphenylethylene citrate (1:1) Referensrad 2	911-45-5	4	Ökar produktion av könshormon, t.ex. testosteron	[1, 16, 18] 2 [19]
Chloro-oxomethyltestosterone	4-chloro-11-oxomethyltestosterone	14935-61-6	4	Androgen/anabol steroid	[20]
Chorionic Gonadotrophin	Human Chorionic Gonadotropin HCG, hCG	9002-61-3	4	Ökar produktion av könshormon, t.ex. testosteron	[21]
CJC-1295	DAC-GRF eller Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-N6-[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-NH ₂	863288-34-0	4	Ökar frisättning av tillväxthormon	[51]
CJC-1295 (no DAC)	Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH ₂	446036-98-2	4	Ökar frisättning av tillväxthormon	[51] [54] [55]
Clostebol	4-Chlortestosterone 4-Chloro-17 β -hydroxyandrosta-4-en-3-one Referensrad 2	1093-58-9	1	Androgen/anabol steroid	[1, 16] 2 [22]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Cyclofenil	Cyclofinil	2624-43-3	4	Selektiv östrogenreceptor modulerare (SERM).	[23-26]
Danazol	17 β -Hydroxy-2,4,17 α -pregnadien-20-yno[2,3-d]isoxazole Pregna-2,4-dien-20-yno(2,3-d)isooxazol-17-ol(17 α) Referensrad 2, 3 17 α -ethynyl-17 β -hydroxyandrost-4-eno[2,3-d]isoxazole Referensrad 4	17230-88-5	1	Androgen/anabol steroid	[1] [16] 2 [27] 3 (28) 4 [6]
Dehydrochlormethyltestosterone	Chlordehydromethyltestosterone 4-Chloro-17 β -hydroxy-17-methyl-1,4-androstadien-3-one 4-chloro-17 β -hydroxy-17 α -methylandrosta- 1,4-dien-3-one 4-Chloro-17 α -methyl-17 β -hydroxy-1,4-androstadiene-3- one Referensrad 2	2446-23-3	1	Androgen/anabol steroid	[6] 2 [28]
Delta 6-methyltestosterone		5585-85-3	1	Androgen/anabol steroid	[20]
DHEA	Dehydroepiandrosteron, prasterone	53-43-0	4	Ökar produktion av könshormon, t.ex. testosteron	[52, 53]
Dienedione	19-norandrost-4,9-diene-3,17-dione Estra-4,9-diene-3,17-dione	5173-46-6	1	Androgen/anabol steroid	[65]
Dihydrotestosterone	4-Dihydrotestosterone 5 α -Androstan-17 β -ol-3-one 5 α -Dihydrotestosterone	521-18-6	1	Androgen/anabol steroid	[1, 16]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Droloxifene	3-[1-[4-(2-Dimethylaminoethoxy)phenyl]-2-phenyl-but-1-enyl]phenol	82413-20-5	4	Selektiv östrogenreceptor modulerare (SERM). Ökar produktion av testosteron,	[29]
Drostanolone 1	17 β -Hydroxy-2 α -methyl-5 α -androstano-3-one Methyldihydrotestosterone Methalone Referensrad 2 Dromostanolone Prometholone Referensrad 2	58-19-5	1	Androgen/anabol steroid	[1] 2 [30]
Epistane	2,3-epithio-17-methylandrostan-17-ol (2 α ,3 α ,5 α ,17 β)-Androstan-17-ol, 2,3-epithio-17-methyl, Hemapolin, Metylepitiostanol	4267-80-5	1	Androgen/anabol steroid	[69, 70, 71]
Ethylestrenol	17 α -Ethyl-17 β -hydroxy-4-estrene 19-Nor-17 α -pregn-4-en-17-ol Referensrad 2 3 4	965-90-2	1	Androgen/anabol steroid	[1] 2 [31] 3 [32] 4 [6]
Exemestane	6-Methyleneandrosta-1,4-diene-3,17-dione	107868-30-4	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Fadrozole	4-(5,6,7,8-Tetrahydroimidazo[1,5- α]pyridin-5-yl)benzotrile 5- <i>p</i> -cyanophenyl-5,6,7,8-tetrahydroimidazol[1,5- α]pyridine	102676-47-1	4	Ökar produktion av könshormon, t.ex. testosteron	[1]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Finrazole	Finrozol 4-[(1R,2R)-3-(4-Fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzotrile	160146-16-7	4	Ökar produktion av könshormon, t.ex. testosteron; aromatashämmare	[33]
Fluoxymesterone	9 α -Fluoro-11 β -hydroxy-17 α -methyl-testosterone 9 α -Fluoro-11 β -, 17 β -dihydroxy-17 α -methyl-androst-4-en-3-one Referensrad 2	76-43-7	1	Androgen/anabol steroid	[16] 2 [34]
Formebolone	11 α -17 β -Dihydroxy-17-methyl-3-oxoandosta-1,4-diene-2-carboxaldehyde 2-Formyl-17 α -methylandrosta-1,4-diene-11 α , 17 β -diol-3-one Referensrad 2	2454-11-7	1	Androgen/anabol steroid	[16] 2 [35]
Formestan	4-Hydroxyandrost-4-ene-3,17-dione 4-OHA	566-48-3	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Fulvestrant	(7 α ,17 β)-7-[9-[(4,4,5,5,-5Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol	129453-61-8	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Furazabol	17 β -Hydroxy-17 α -methyl-5 α -androstano[2,3-c]-furazan 17-Methyl-5 α -androstano(2,3-c) (1,2,5) -oxadiazol-17 β -ol Referensrad 2 Androfurazanol	1239-29-8	1	Androgen/anabol steroid	[1] 2 [36]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Ghrelin	GH releasing peptide Growth hormone releasing peptide GHRP	304853-26-7	4	Frisättning av tillväxthormon	[37,49]
GHRP-2	D-Ala-D-Nal-Ala-Trp-D-Phe-Lys-NH ₂	158861-67-7 (acetatsalt)	4	Frisättning av tillväxthormon	[50]
GHRP-6	His-D-Trp-Ala-Trp-D-Phe-Lys-NH ₂	87616-84-0 (acetatsalt)	4	Frisättning av tillväxthormon	[6, 50]
Growth hormone	Somatotropin	9002-72-6	3	Mänskligt tillväxthormon	[1, 26]
Growth Hormone Releasing Hormone	GHRF 1-44 GHRH somatorelin	83930-13-6	4	Mänskligt tillväxthormon	[66, 67, 68]
Hexarelin	Examorelin	140703-51-1	4	Frisättning av tillväxthormon	[50]
Ibutamoren	MK-677; Propanamide, 2-amino- <i>N</i> -[(1 <i>R</i>)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3 <i>H</i> -indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-	159634-47-6	4	Frisättning av tillväxthormon	[62, 63]
Idoxifene	CB4227788 (<i>E</i>)-1-(2-(4-(1-(4-Iodophenyl)-2-phenyl-1-butenyl)phenoxy)ethyl)pyrrolidine	116057-75-1	4	Ökar produktion av könshormon, t.ex. testosteron; (SERM)	[1, 9, 38]
Ipamorelin	2-methylalanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl- L-Lysinamide	170851-70-4	4	Frisättning av tillväxthormon	[61]
Lasoxifene	Lasodoxifene	180916-16-9	4	Ökar produktion av könshormon, t.ex. testosteron; (SERM)	[9, 39]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Letrozole	4,4'-(1 <i>H</i> -1,2,4-Triazol-1-ylmethylene)bisbenzotrile 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole 4-[1-(4-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl]benzotrile	112809-51-5	4	Ökar produktion av könshormon, t.ex. testosteron	[1, 25]
Mestanolone	17 α -Methylandrostan-17 β -ol-3-one 17 α -Methyl-17 β -hydroxy-5 α -androstan-3-one Referensrad 2 17 α -Methyldihydrotestosterone Referensrad 2	521-11-9	1	Androgen/anabol steroid	[1] 2 [40]
Mesterolone	1 α -Methyl-5 α -androstan-17 β -ol-3-one 17 β -Hydroxy-1 α -methyl-5 α -androstan-3-one Referensrad 2	1424-00-6	1	Androgen/anabol steroid	[1] [16] 2 [41]
Methandriol	(3 β ,17 β)-17-Methylandrost-5-ene-3,17-diol 17 α -Methyl-androst-5-ene-3 β , 17 β -diol Methylandrostenediol	521-10-8	1	Androgen/anabol steroid	[1] [16] [42]
Methandrostenolone	17 α -Methyl-17 β -hydroxyandrosta-1,4-dien-3-one 1-Dehydro-17 α -metyltestosterone Referensrad 2 Metandienone	72-63-9	1	Androgen/anabol steroid	[1] [16] 2 [43]
Methenolone	1-Methyl- Δ 1-androsten-17 β -ol-3-one (5 α , 17 β)-17-hydroxy-1-methylandrost-1-en-3-one	153-00-4	1	Androgen/anabol steroid	[1, 16]
Methyldienolone	17-hydroxy-17-methyl-estra-4,9-dien-3-one 17 β -hydroxy-17 α -methylestra-4,9-dien-3-one	14531-89-6	1	Androgen/anabol steroid	[58,59,60]
Methyldrostanolon	17 β -Hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-ol	3381-88-2	1	Androgen/anabol steroid	[6,20]
Methylstenbolone	2,17-dimethyl-17-hydroxy-androst-1-en-3-one (5 α ,17 β)-2,17-dimethyl-17-hydroxy-androst-1-en-3-one	6176-38-1	1	Androgen/anabol steroid	[72, 73]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Methyltestosterone	17 β -Hydroxy-17 α -methyl-androst-4-en-3-one 17-Methyltestosterone	58-18-4	1	Androgen/anabol steroid	[1, 26]
Methyltrienolone	17 β -Hydroxy-17-methyl-19-norandrosta-4,9,11-trien-3-one 17 α -Methyl-4,9,11-estratrien-17 β -ol-3-one 17 β -hydroxy-17 α -methylestra-4,9,11-trien-3-one <small>Referensrad 2</small>	965-93-5	1	Androgen/anabol steroid	[1] 2 [6]
Mibolerone	7 α ,17 α -Dimethyl-19-nortestosterone 17 β -Hydroxy-7 α ,17-dimethylestr-4-en-3-one Dimetylnortestosterone	3704-09-4	1	Androgen/anabol steroid	[1, 26]
Nandrolone	4-Estren-17 β -ol-3-one 17 β -Hydroxy-4-estren-3-one 3-Oxoestr-4-en-17 β -yl 19-Nortestosterone	434-22-0	1	Androgen/anabol steroid	[1, 26, 44]
Norbolethone	dl-13 β ,17 α -Diethyl-17 β -hydroxygon-4-en-3-one 17 α -(+/-)-13-Ethyl-17-hydroxy-18,19-dinor-pregn-4-en-3-one	1235-15-0	1	Androgen/anabol steroid	[1, 45]
Norethandrolone	17 α -Ethyl-19-nortestosterone 17 β -Hydroxy-19-nor-17 α -pregn-4-en-3-one	52-78-8	1	Androgen/anabol steroid	[26, 43]
Normethandrone	17 β -17-Hydroxy-17-methylestr-4-en-3-one 17 α -Methyl-19-nortestosterone Methylestrenolone	514-61-4	1	Androgen/anabol steroid	[1]
Oxabolone	17 β -4,17-Dihydroxyestr-4-en-3-one 4-Hydroxy-19-nortestosterone	4721-69-1	1	Androgen/anabol steroid	[1, 16]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Oxandrolone	Dodecahydro-3-hydroxy-6-hydroxymethyl-3,3a,6-trimethyl-1H-benz[e]indene-7-acetic acid δ -lactone 5 α ,17 β -17-Hydroxy-17-methyl-2-oxaandrostan-3-one	53-39-4	1	Androgen/anabol steroid	[1, 26]
Oxymesterone	17 β -4,17-Dihydroxy-17-methylandrosta-4-en-3-one 4,17 β -Dihydroxy-17 α -methyl-3-oxandrosta-4-ene 4-Hydroxy-17 α -methyltestosterone	145-12-0	1	Androgen/anabol steroid	[1]
Oxymetholone	17 β -Hydroxy-2-hydroxymethylene-17 α -methyl-5 α -androsta-3-one 2-Hydroxy-methylene-17 α -methyl-dihydro-testosterone Anasterone	434-07-1	1	Androgen/anabol steroid	[1, 26]
Quinbolone	17 β -17-(1-Cyclopenten-1-yloxy)androsta-1,4-dien-3-one 1-Dehydrotestosterone 17-cyclopent-1'-enyl ether	2487-63-0	1	Androgen/anabol steroid	[1, 16]
Raloxifene	[6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiene-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone	84449-90-1	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Stanozolol	17 α -Methyl-5 α -androsta-17 β -olo(3,2-c)pyrazole Androstanazol	10418-03-8	1	Androgen/anabol steroid	[1, 26]
Stenbolone	2-Methyl-5 α -androsta-1-en-17 β -ol-3-one	5197-58-0	1	Androgen/anabol steroid	[1]
Tamoxifen	(<i>Z</i>)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy] <i>N,N</i> -dimethylethanamine 1- <i>p</i> - β dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene	10540-29-1	4	Ökar produktion av könshormon, t.ex. testosteron	[1]



Substans	Andra namn	CAS-nr	Klass enl 1 § lag (1991:1969)	Effekt/Övrigt	Referenser
Testolactone	D-homo-17a-oxandrosta-1,4-diene-3,17-dione Delta-1-testololactone 1-Dehydrotestololactone Fludestrin	968-93-4	4	Ökar produktion av könshormon, t.ex. testosteron	[1, 26, 46]
Testosterone	4-Androsten-17β-ol-3-one Δ ⁴ -Androsten-17β-ol-3-one 17β-17-Hydroxyandrost-4-en-3-one 17β-hydroxy-5α-androst-1-en-3-one	58-22-0	2	Androgen/anabol steroid	[1, 26, 47] [6]
Tetrahydrogestrinone	13β-17α-Diethyl-17β-hydroxygon-4,9,11-trien-3-one 18a-homo-pregna-4,9,11-trien-17β-ol-3-one	618-903-56-3	1	Androgen/anabol steroid	[45] [6]
Tiomesterone	1α,7α-Bis(acetylthio)-17α-methyltestosterone 17β-Hydroxy-1α,7α-dimercapto-17-methylandrost-4-en-3-one 1,7-diacetate	2205-73-4	1	Androgen/anabol steroid	[1]
Toremifene	2-[4-[(1Z)-4-Chloro-1,2-diphenyl-1butenyl]phenoxy]-N,N-dimethylethanamine (Z)-4-chloro-1,2-diphenyl-1-[4-[2-N,N-dimethylamino)ethoxy]phenyl]-1-butene	89778-26-7	4	Ökar produktion av könshormon, t.ex. testosteron	[1]
Trenbolone	17β-Hydroxyestra-4,9,11-trien-3-one 19-Norandrosta-4,9,11-trien-17β-ol-3-one Trienbolone Trienolone	10161-33-8	1	Androgen/anabol steroid	[1, 26]
Trestolone	MENT; Estr-4-en-3-one, 17-hydroxy-7-methyl-, (7α,17β)-	3764-87-2	1	Androgen/anabol steroid	[64]
Vorozole	6-[(S)-(4-Chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-1H-benzotriazole	129731-10-8	4	Ökar produktion av könshormon, t.ex. testosteron	[1]

Expertgruppens förteckning över Dopningsmedel enligt dopningslagen (1991:1969)

Bifogade förteckning över dopningsmedel enligt dopningslagen är avsedd som ett stöd i det praktiska arbetet för rättsväsendet, myndigheter, organisationer och institutioner. Samtliga substanser är namngivna på engelska.

Dopningslagens konstruktion medför att förteckningen är en tolkning av dopningslagen och därför är den per definition inofficiell. Med utgångspunkt från i dag kända och i missbrukssammanhang förekommande substanser har en bedömning gjorts av vad som enligt lagen skall betraktas som dopningsmedel. Till skillnad från narkotikastrafflagen eller lagen om förbud mot vissa hälsofarliga varor saknar dopningslagen referens till internationella överenskommelser och/eller regeringsbeslut om vilka varor/substanser/preparat som omfattas av lagen. Det innebär att substanser som inte finns upptagna i bifogade förteckning ändå kan utgöra dopningsmedel enligt dopningslagen. Det gäller t ex salter, isomerer, salter av isomerer, estrar, etrar samt olika derivat av de förtecknade modersubstanserna.

För att upprätta förteckningen över substanser som utgör dopningsmedel enligt lagen (1991:1969) om förbud mot vissa dopningsmedel har en expertgrupp bildats i samarbete mellan myndigheter, institutioner och organisationer som är berörda av dopningens skadeverkningar och problem. Expertgruppen består av representanter från Centrum för Andrologi och Sexualmedicin samt Dopinglaboratoriet vid Karolinska Universitetssjukhuset, Livsmedelsverket, Åklagarmyndighetens utvecklingscentrum Stockholm, Rättsmedicinalverket, Läkemedelsverket, Nationellt Forensiskt Centrum, Tullverkets laboratorium och Folkhälsomyndigheten.

Förslag till förteckning över dopningspreparat upprättas i samverkan mellan Dopinglaboratoriet, Nationellt Forensiskt Centrum och Tullverkets laboratorium. Förteckningen fastställs av den samlade expertgruppen.

Folkhälsomyndigheten administrerar expertgruppens arbete och har expertgruppens mandat att på Folkhälsomyndighetens webbsida publicera expertgruppens förteckning över dopningsmedel enligt dopningslagen.

Förteckningen över dopningspreparat granskas fortlöpande av expertgruppen och ändringar i förteckningen sker när så är motiverat. När expertgruppen enats om en ny version av förteckningen publiceras den på Folkhälsomyndighetens webbsida och ersätter då tidigare versioner. I sidhuvudet på varje ny förteckning finns utgåvans nummer samt ett datum som anger när förteckningen beslutades av expertgruppen.

SERM är en förkortning för selective estrogen receptor modulators.



Referenser

1. O'Neil, M., et al., eds. *The Merck index: An Encyclopedia of Chemicals, Drugs, and Biologicals*. Vol. Fourteenth Edition. 2006, Merck & Co., Inc. : Whitehouse Station, New Jersey, USA.
2. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 360-66-7*. 2006 [cited 2006 10 oktober]; Available from: [CAS-Nr: 360-66-7](#).
3. Tsai-Morris, C.H., D.R. Aquilano, and M.L. Dufau, *Gonadotropic regulation of aromatase activity in the adult rat testis*. *Endocrinology*, 1985. **116**(1): p. 31-7.
4. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 521-17-5*. 2006 [cited 2006 10 oktober]; Available from: [CAS-Nr: 521-17-5](#).
5. Comparative Toxicogenomics Database (CTD). *Androstenediol*. 2006 [cited 2006 20 oktober]; Available from: [Androstenediol](#).
6. World Anti-Doping Agency (WADA). *The 2007 prohibited list*. 2007 [cited 2007 30 mars]; Available from: [The 2007 prohibited list](#).
7. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 53-41-8*. 2006 [cited 2006 20 oktober]; Available from: [CAS-Nr: 53-41-8](#).
8. Comparative Toxicogenomics Database (CTD). *Androsterone*. 2006 [cited 2006 20 oktober]; Available from: [Androsterone](#).
9. Handelsman, D.J., *Indirect androgen doping by oestrogen blockade in sports*. *Br J Pharmacol*, 2008. **154**(3): p. 598-605.
10. Muller, M., et al., *Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men*. *J Clin Endocrinol Metab*, 2006. **91**(10): p. 3988-91.
11. Chines, A.A. and B.S. Komm, *Bazedoxifene acetate: A novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis*. *Drugs Today (Barc)*, 2009. **45**(7): p. 507-20.
12. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 19793-20-5*. 2006 [cited 2006 20 oktober]; Available from: [CAS-Nr: 19793-20-5](#).
13. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 1605-89-6*. 2006 [cited 2006 20 oktober]; Available from: [CAS-Nr: 1605-89-6](#).
14. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 846-48-0*. 2006 [cited 2006 10 oktober]; Available from: [CAS-Nr: 846-48-0](#).
15. Comparative Toxicogenomics Database (CTD). *Boldenone*. 2006 [cited 2006 10 oktober]; Available from: [Boldenone](#).
16. Martindale, W. and J.E.F. Reynolds, *The extra pharmacopoeia: the universally acclaimed source of drug information*. Vol. 30. rev. ed. 1993, London: Pharmaceutical Press.
17. Comparative Toxicogenomics Database (CTD). *Calusterone*. 2006 [cited 2006 10 oktober]; Available from: [Calusterone](#).
18. Läkemedelsindustriföreningen and FASS.se för forskrivare. *Klomifen*. 2006 [cited 2006 27 oktober]; Available from: [Klomifen](#).
19. Comparative Toxicogenomics Database (CTD). *Clomiphene*. 2006 [cited 2006 10 oktober]; Available from: [Clomiphene](#).
20. Vida, J., *Androgens and Anabolic Agents, Chemistry and Pharmacology*. 1969, New York and London: Academic Press.



21. Läkemedelsindustriföreningen and FASS.se för förskrivare. *Koriongonadotropin*. 2006 [cited 2006 27 oktober]; Available from: [Koriongonadotropin](#).
22. Comparative Toxicogenomics Database (CTD). *Clotestebol*. 2006 [cited 2006 10 oktober]; Available from: [Clotestebol](#).
23. Gartner, P., et al., *Synthesis and identification of hydroxylated metabolites of the anti-estrogenic agent cyclofenil*. Journal of mass spectrometry, 2008. **43**: p. 958-964.
24. Bowman, Leaka, and Morris, *Biological activity and steroid receptor interaction of cyclofenil with the oestrogen target tissues of the brain pituitary gland and uterus of the rat*. J. Reprod. Fert., 1982. **65**: p. 355-356.
25. Mareck, U., et al., *Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry*. Rapid Commun Mass Spectrom, 2005. **19**(24): p. 3689-93.
26. Martindale, W. and S.C. Sweetman, *Martindale: the completed drug reference*. Vol. 33 ed. 2002, London: Pharmaceutical press.
27. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 17230-88-5*. 2006 [cited 2006 20 oktober]; Available from: [CAS-Nr: 17230-88-5](#).
28. Comparative Toxicogenomics Database (CTD). *Oral-turinabol*. 2006 [cited 2006 20 oktober]; Available from: [Oral-turinabol](#).
29. Shelly, W., et al., *Selective estrogen receptor modulators: an update on recent clinical findings*. Obstet Gynecol Surv., 2008. **Mar**; **63**(3):163-81. **Review**.
30. Comparative Toxicogenomics Database (CTD). *Dromostanolone*. 2006 [cited 2006 20 oktober]; Available from: [Dromostanolone](#).
31. Cambridge Soft Corporation and ChemFinder.com. *CAS-Nr: 965-90-2*. 2006 [cited 2006 20 oktober]; Available from: [CAS-Nr: 965-90-2](#).
32. Comparative Toxicogenomics Database (CTD). *Ethylestrenol*. 2006 [cited 2006 20 oktober]; Available from: [Ethylestrenol](#).
33. Ahokoski, O., et al., *A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects*. Eur J Clin Pharmacol, 1999. **55**(1): p. 27-34.
34. Sigma-Aldrich. *Fluoxymesterone*. 2006 [cited 2006 27 oktober]; Available from: [Fluoxymesterone](#).
35. Comparative Toxicogenomics Database (CTD). *Formebolone*. 2006 [cited 2006 20 oktober]; Available from: [Formebolone](#).
36. Comparative Toxicogenomics Database (CTD). *Furazabol*. 2006 [cited 2006 20 oktober]; Available from: [Furazabol](#).
37. Anderson, L.L., et al., *Physiology of ghrelin and related peptides*. Domest Anim Endocrinol, 2005. **29**(1): p. 111-44.
38. Shelly, W., et al., *Selective estrogen receptor modulators: an update on recent clinical findings*. Obstet Gynecol Surv, 2008. **63**(3): p. 163-81.
39. Gennari, L., *Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy*. Expert Opin Pharmacother, 2009. **10**(13): p. 2209-20.
40. Comparative Toxicogenomics Database (CTD). *Mestanolone*. 2006 [cited 2006 20 oktober]; Available from: [Mestanolone](#).
41. Comparative Toxicogenomics Database (CTD). *Mesterolone*. 2006 [cited 2006 20 oktober]; Available from: [Mesterolone](#).



42. Comparative Toxicogenomics Database (CTD). *Methandriol*. 2006 [cited 2006 20 oktober]; Available from: [Methandriol](#).
43. Comparative Toxicogenomics Database (CTD). *Methandrostenolone*. 2006 [cited 2006 20 oktober]; Available from: [Methandrostenolone](#).
44. Läkemedelsindustriföreningen and FASS.se för förskrivare. *Nandrolon*. 2006 [cited 2006 27 oktober]; Available from: [Nandrolon](#).
45. United States Anti-Doping Agency (USADA), *2005 guide to prohibited substances and prohibited methods of doping*. 2005, Colorado Springs, USA: United States Anti-Doping Agency (USADA),.
46. Braunstein, G.D., *Aromatase and gynecomastia*. *Endocr Relat Cancer*, 1999. 6(2): p. 315-24.
47. Läkemedelsindustriföreningen and FASS.se för förskrivare. *Testosteron*. 2006 [cited 2006 27 oktober]; Available from: [Testosteron](#).
48. Yunje Kim*, *Myungyoon Jun and Won Lee. Characterization of boldione and its metabolites in human urine by liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry*. *Rapid Commun. Mass Spectrom*. 2006; 20: 9–20
49. Korbonits, M., Goldstone, A. P., Gueorguiev, M., & Grossman, A. B. (2004). Ghrelin--a hormone with multiple functions. *Front Neuroendocrinol*, 25(1), 27-68
50. Moulin, A., Ryan, J., Martinez, J., & Fehrentz, J.-A. Recent Developments in Ghrelin Receptor Ligands.
51. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. *J Clin Endocrinol Metab*, 91(3), 799-805.
52. Maggi, M., Buvat, J., Corona, G., Guay, A., & Torres, L. O. (2013). Hormonal causes of male sexual dysfunctions and their management (hyperprolactinemia, thyroid disorders, GH disorders, and DHEA). *J Sex Med*, 10(3), 661-677.
53. Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012). Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? *Endocr Rev*, 33(3), 314-377.
54. Lucila Sackmann-Sala, Juan Ding, Lawrence A Frohman and John J Kopchick.(2009) Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. *Growth Horm IGF Res*. Dec 2009; 19(6): 471–477.
55. Madalina Ionescu, and Lawrence A. Frohman (2006) Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. *J Clin Endocrinol Metab*. 2006 Dec;91(12):4792-7.
A novel in-silico approach for QSAR Studies of Anabolic and Androgenic Activities in the 17b-hydroxy-5a-androstane Steroid Family, Yoanna Mar_a Alvarez-Ginartea, b, Rachel Crespob, Luis Alberto Montero-Cabrera*, Jose´ Alberto Ruiz-Garciaa, Yovani Marrero Ponced, Roberto Santanac, Eladio Pardillo-Fontdevilaa, Esther Alonso-Becerrab QSAR & Combinatorial Science
56. Volume24 Issue2 Pages218-226 Journal 2005 CODEN:QCSSAU ISSN:1611-020X DOI:10.1002/qsar.200430889



57. Endocrine characterization of the designer steroid methyl-1-testosterone: investigations on tissue-specific anabolic-androgenic potency, side effects, and metabolism. By: Parr, Maria K.; Blatt, Christina; Zierau, Oliver; Hess, Cornelius; Guetschow, Michael; Fusshoeller, Gregor; Opfermann, Georg; Schaenzer, Wilhelm; Diel, Patrick *Endocrinology*. Volume152. Issue12. Pages4718-4728. journal 2011 CODEN:ENDOAO ISSN:0013-7227 DOI:10.1210/en.2011-1164
58. Anabolic and androgenic activities of 19-nor-testosterone steroids: QSAR study using quantum and physicochemical molecular descriptors By: Alvarez-Ginarte, Yoanna Maria; Montero-Cabrera, Luis Alberto; de la Vega, Jose Manuel Garcia; Noheda-Marin, Pedro; Marrero-Ponce, Yovani; Ruiz-Garcia, Jose Alberto *Journal of Steroid Biochemistry and Molecular Biology* Volume126 Issue1-2 Pages35-45 Journal; Online Computer File 2011 CODEN:JSBBEZ ISSN:0960-0760 DOI:10.1016/j.jsbmb.2011.04.003
59. Estradienes and 2-Oxaestradienes. Potent Oral Anabolic-Androgenic Agents E. F. NUTTING, and D. W. CALHOUN DOI: <http://dx.doi.org/10.1210/endo-84-2-441> Received: July 15, 1968 First Published Online: July 01, 2013
60. Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine. Fragkaki AG1, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. *J Steroid Biochem Mol Biol*. 2009 May;115(1-2):44-61. doi: 10.1016/j.jsbmb.2009.02.016. Epub 2009 Mar 4
61. Ipamorelin, the first selective growth hormone secretagogue. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. *Eur J Endocrinol*. 1998 Nov;139(5):552-61.
62. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. *Mol Endocrinol*. 2005 Sep;19(9):2400-11. Epub 2005 May 19.
63. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA. *J Clin Endocrinol Metab*. 1998 Feb;83(2):362-9
64. 7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception. Sundaram K, Kumar N, Bardin CW. *Ann Med*. 1993 Apr;25(2):199-205. Review.
65. Scarth JP, Clarke AD, Teale P, Pearce CM. Comparative in vitro metabolism of the 'designer' steroid estra-4,9-diene-3,17-dione between the equine, canine and human: identification of target metabolites for use in sports doping control. *Steroids*. 2010;75(10):643-52.
66. Boissel JP, Cohen R, Biot-Laporte S, Claustrat B, Renard H, Olivier M, et al. Synthetic human growth hormone releasing factor (h-GRF-I-44-NH2) dose response effect on growth hormone and prolactin secretion in healthy adult men. *Eur J Clin Pharmacol*. 1986;29(5):609-14.
67. Serri O, Somma M, Rasio E, Brazeau P. Growth hormone-releasing factor increases serum prolactin concentrations in normal subjects and in patients with pituitary adenomas. *Clin Endocrinol (Oxf)*. 1989;30(1):65-75.



68. Wit JM, Otten BJ, Waelkens JJ, Oostdijk W, Krabbe J, Rochefort JG, et al. Short-term effect on growth of two doses of GRF 1-44 in children with growth hormone deficiency: comparison with growth induced by methionyl-GH administration. *Horm Res.* 1987;27(4):181-9.
69. Miyake T, Hori T, Kato G, Ide M, Uchida N, Yamaguchi K. 2Alpha, 3alpha-epithio-5alpha-androstan-17beta-YL 1-methoxycyclopentyl ether (10364-S), a new orally active anti-estrogenic steroid. *Steroids.* 1974;23(6):929-37
70. Masato Okano,* Mitsuhiro Sato, Ayako Ikekita and Shinji Kageyama. Analysis of non-ketotic steroids 17 α -methyl-epithiostanol and desoxymethyltestosterone in dietary supplements. *Drug Test. Analysis* 2009, 1, 518–525
71. C. D. Rahnema, L. E. Crosnoe and E. D. Kim. Designer steroids – over-the-counter supplements and their androgenic component: review of an increasing problem. *Andrology* 2015 doi: 10.1111/andr.307
72. Geldof L, Lootens L, Polet M, Eichner D, Campbell T, Nair V, et al. Metabolism of methylstenbolone studied with human liver microsomes and the uPA(+)/(+)-SCID chimeric mouse model. *Biomed Chromatogr.* 2014;28(7):974-85.
73. Gustavo de Albuquerque Cavalcanti, Felipe Dias Leal, Bruno Carius Garrido, Monica Costa Padilha, Francisco Radler de Aquino Neto. Detection of designer steroid methylstenbolone in “nutritional supplement” using gas chromatography and tandem mass spectrometry: Elucidation of its urinary metabolites. *Steroids* (2012), <http://dx.doi.org/10.1016/j.steroids.2012.11.009>
74. Kanno Y, Hikosaka R, Zhang SY, Inoue Y, Nakahama T, Kato K, et al. (17 α ,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene -21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor. *Biol Pharm Bull.* 2011;34(3):318-23.
75. Kanno Y, Ota R, Someya K, Kusakabe T, Kato K, Inouye Y. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. *Biol Pharm Bull.* 2013;36(9):1460-5.
76. Thomas Piper, Josef Dib, Marlen Putz, Gregor Fusshöller, Valentin Pop, Andreas Lagojda, Dirk Kuehne, Hans Geyer, Wilhelm Schänzer, Mario Thevis. Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls doi:10.1002/dta.2527.
77. Tomofumi Yatsu, Taichi Kusakabe, Keisuke Kato, Yoshio Inouye, Kiyomitsu Nemoto, and Yuichiro Kanno. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells *Biol. Pharm. Bull.* 41, 394–398 (2018).
78. A. Friedel a, H. Geyerc, M. Kamberd, U. Laudenschowsky a, W. Schänzer c, M. Thevis c, G. Vollmer b, O. Zierau b, P. Diel a,*.
17 β -Hydroxy-5 α -androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. *Toxicology Letters*, Volume 165, Issue 2, 20 August 2006, Pages 149-155
79. Kwok WH1, Ho EN, Leung GN, Tang FP, Wan TS, Wong HN, Yeung JH. Metabolic studies of 1-testosterone in horses. *Drug Test Anal.* 2013 Feb;5(2):81-8. doi: 10.1002/dta.1380. Epub 2012 Jun 20.



Folkhälsomyndigheten

Sidan 18 av 18

Folkhälsomyndigheten

*Postadress:
Box 505
831 26 ÖSTERSUND*

Besöksadress: Campusvägen 20

Telefon:

Vx 010 205 20 00

Telefax:

Vx 08 – 32 83 30

E-post:

info@folkhalsomyndigheten.se